Global Human Plasma-derived Hyperimmune Product Supply, Demand and Key Producers, 2024-2030

Description

The global Human Plasma-derived Hyperimmune Product market size is expected to reach $ 2866.8 million by 2030, rising at a market growth of 5.9% CAGR during the forecast period (2024-2030).

The human plasma-based hyperimmune preparation market is driven by the increasing demand for effective treatments against specific infectious diseases and other medical conditions. Hyperimmune preparations are derived from the plasma of individuals who have recovered from a particular infection or have been vaccinated against a specific pathogen. These preparations contain high levels of antibodies targeting the specific pathogen or antigen, making them valuable for passive immunization in individuals at risk or currently affected by the same disease. The growing prevalence of infectious diseases, such as COVID-19, and the need for rapid and targeted therapeutic solutions have fueled market growth. Moreover, advancements in plasma fractionation and purification technologies have improved the production and safety of hyperimmune preparations. However, the market also faces challenges, including the complexity of large-scale plasma collection and processing, ensuring consistent antibody levels in the preparations, and maintaining a robust supply chain to meet demand during disease outbreaks or pandemics. Additionally, regulatory considerations and the need for stringent safety and quality standards are crucial challenges for manufacturers. To succeed in this market, companies must focus on research and development to expand the applications of hyperimmune preparations, collaborate with healthcare authorities and organizations to establish guidelines and protocols, and work towards enhancing plasma collection infrastructure to ensure a steady supply of human plasma-based hyperimmune preparations for critical therapeutic interventions.

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

This report studies the global Human Plasma-derived Hyperimmune Product production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Human Plasma-derived Hyperimmune Product, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Human Plasma-derived Hyperimmune Product that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Human Plasma-derived Hyperimmune Product total production and demand, 2019-2030, (K Units)
Global Human Plasma-derived Hyperimmune Product total production value, 2019-2030, (USD Million)
Global Human Plasma-derived Hyperimmune Product production by region & country, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Human Plasma-derived Hyperimmune Product consumption by region & country, CAGR, 2019-2030 & (K Units)
U.S. VS China: Human Plasma-derived Hyperimmune Product domestic production, consumption, key domestic manufacturers and share
Global Human Plasma-derived Hyperimmune Product production by manufacturer, production, price, value and market share 2019-2024, (USD Million) & (K Units)
Global Human Plasma-derived Hyperimmune Product production by Type, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Human Plasma-derived Hyperimmune Product production by Application production, value, CAGR, 2019-2030, (USD Million) & (K Units).

This reports profiles key players in the global Human Plasma-derived Hyperimmune Product market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CSL Behring, Grifols, Biotest, Kedrion, CBPO, Emergent (Cangene), Kamada, CNBG and Hualan Bio, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Human Plasma-derived Hyperimmune Product market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Human Plasma-derived Hyperimmune Product Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Human Plasma-derived Hyperimmune Product Market, Segmentation by Type
    Hepatitis B Immunoglobulins
    Rabies Immunoglobulins
    Tetanus Immunoglobulins
    Rho(D) Immunoglobulins
    Other

Global Human Plasma-derived Hyperimmune Product Market, Segmentation by Application
    Government Institution
    Private Sector
    Others

Companies Profiled:
    CSL Behring
    Grifols
    Biotest
    Kedrion
    CBPO
    Emergent (Cangene)
    Kamada
    CNBG
    Hualan Bio
    Shanghai RAAS
    Sichuan Yuanda Shuyang
    ADMA Biologics

Key Questions Answered
1. How big is the global Human Plasma-derived Hyperimmune Product market?
2. What is the demand of the global Human Plasma-derived Hyperimmune Product market?
3. What is the year over year growth of the global Human Plasma-derived Hyperimmune Product market?
4. What is the production and production value of the global Human Plasma-derived Hyperimmune Product market?
5. Who are the key producers in the global Human Plasma-derived Hyperimmune Product market?

Table of Contents

1 Supply Summary
    1.1 Human Plasma-derived Hyperimmune Product Introduction
    1.2 World Human Plasma-derived Hyperimmune Product Supply & Forecast
        1.2.1 World Human Plasma-derived Hyperimmune Product Production Value (2019 & 2023 & 2030)
        1.2.2 World Human Plasma-derived Hyperimmune Product Production (2019-2030)
        1.2.3 World Human Plasma-derived Hyperimmune Product Pricing Trends (2019-2030)
    1.3 World Human Plasma-derived Hyperimmune Product Production by Region (Based on Production Site)
        1.3.1 World Human Plasma-derived Hyperimmune Product Production Value by Region (2019-2030)
        1.3.2 World Human Plasma-derived Hyperimmune Product Production by Region (2019-2030)
        1.3.3 World Human Plasma-derived Hyperimmune Product Average Price by Region (2019-2030)
        1.3.4 North America Human Plasma-derived Hyperimmune Product Production (2019-2030)
        1.3.5 Europe Human Plasma-derived Hyperimmune Product Production (2019-2030)
        1.3.6 China Human Plasma-derived Hyperimmune Product Production (2019-2030)
        1.3.7 Japan Human Plasma-derived Hyperimmune Product Production (2019-2030)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Human Plasma-derived Hyperimmune Product Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Human Plasma-derived Hyperimmune Product Major Market Trends

2 Demand Summary
    2.1 World Human Plasma-derived Hyperimmune Product Demand (2019-2030)
    2.2 World Human Plasma-derived Hyperimmune Product Consumption by Region
        2.2.1 World Human Plasma-derived Hyperimmune Product Consumption by Region (2019-2024)
        2.2.2 World Human Plasma-derived Hyperimmune Product Consumption Forecast by Region (2025-2030)
    2.3 United States Human Plasma-derived Hyperimmune Product Consumption (2019-2030)
    2.4 China Human Plasma-derived Hyperimmune Product Consumption (2019-2030)
    2.5 Europe Human Plasma-derived Hyperimmune Product Consumption (2019-2030)
    2.6 Japan Human Plasma-derived Hyperimmune Product Consumption (2019-2030)
    2.7 South Korea Human Plasma-derived Hyperimmune Product Consumption (2019-2030)
    2.8 ASEAN Human Plasma-derived Hyperimmune Product Consumption (2019-2030)
    2.9 India Human Plasma-derived Hyperimmune Product Consumption (2019-2030)

3 World Human Plasma-derived Hyperimmune Product Manufacturers Competitive Analysis
    3.1 World Human Plasma-derived Hyperimmune Product Production Value by Manufacturer (2019-2024)
    3.2 World Human Plasma-derived Hyperimmune Product Production by Manufacturer (2019-2024)
    3.3 World Human Plasma-derived Hyperimmune Product Average Price by Manufacturer (2019-2024)
    3.4 Human Plasma-derived Hyperimmune Product Company Evaluation Quadrant
    3.5 Industry Rank and Concentration Rate (CR)
        3.5.1 Global Human Plasma-derived Hyperimmune Product Industry Rank of Major Manufacturers
        3.5.2 Global Concentration Ratios (CR4) for Human Plasma-derived Hyperimmune Product in 2023
        3.5.3 Global Concentration Ratios (CR8) for Human Plasma-derived Hyperimmune Product in 2023
    3.6 Human Plasma-derived Hyperimmune Product Market: Overall Company Footprint Analysis
        3.6.1 Human Plasma-derived Hyperimmune Product Market: Region Footprint
        3.6.2 Human Plasma-derived Hyperimmune Product Market: Company Product Type Footprint
        3.6.3 Human Plasma-derived Hyperimmune Product Market: Company Product Application Footprint
    3.7 Competitive Environment
        3.7.1 Historical Structure of the Industry
        3.7.2 Barriers of Market Entry
        3.7.3 Factors of Competition
    3.8 New Entrant and Capacity Expansion Plans
    3.9 Mergers, Acquisition, Agreements, and Collaborations

4 United States VS China VS Rest of the World
    4.1 United States VS China: Human Plasma-derived Hyperimmune Product Production Value Comparison
        4.1.1 United States VS China: Human Plasma-derived Hyperimmune Product Production Value Comparison (2019 & 2023 & 2030)
        4.1.2 United States VS China: Human Plasma-derived Hyperimmune Product Production Value Market Share Comparison (2019 & 2023 & 2030)
    4.2 United States VS China: Human Plasma-derived Hyperimmune Product Production Comparison
        4.2.1 United States VS China: Human Plasma-derived Hyperimmune Product Production Comparison (2019 & 2023 & 2030)
        4.2.2 United States VS China: Human Plasma-derived Hyperimmune Product Production Market Share Comparison (2019 & 2023 & 2030)
    4.3 United States VS China: Human Plasma-derived Hyperimmune Product Consumption Comparison
        4.3.1 United States VS China: Human Plasma-derived Hyperimmune Product Consumption Comparison (2019 & 2023 & 2030)
        4.3.2 United States VS China: Human Plasma-derived Hyperimmune Product Consumption Market Share Comparison (2019 & 2023 & 2030)
    4.4 United States Based Human Plasma-derived Hyperimmune Product Manufacturers and Market Share, 2019-2024
        4.4.1 United States Based Human Plasma-derived Hyperimmune Product Manufacturers, Headquarters and Production Site (States, Country)
        4.4.2 United States Based Manufacturers Human Plasma-derived Hyperimmune Product Production Value (2019-2024)
        4.4.3 United States Based Manufacturers Human Plasma-derived Hyperimmune Product Production (2019-2024)
    4.5 China Based Human Plasma-derived Hyperimmune Product Manufacturers and Market Share
        4.5.1 China Based Human Plasma-derived Hyperimmune Product Manufacturers, Headquarters and Production Site (Province, Country)
        4.5.2 China Based Manufacturers Human Plasma-derived Hyperimmune Product Production Value (2019-2024)
        4.5.3 China Based Manufacturers Human Plasma-derived Hyperimmune Product Production (2019-2024)
    4.6 Rest of World Based Human Plasma-derived Hyperimmune Product Manufacturers and Market Share, 2019-2024
        4.6.1 Rest of World Based Human Plasma-derived Hyperimmune Product Manufacturers, Headquarters and Production Site (State, Country)
        4.6.2 Rest of World Based Manufacturers Human Plasma-derived Hyperimmune Product Production Value (2019-2024)
        4.6.3 Rest of World Based Manufacturers Human Plasma-derived Hyperimmune Product Production (2019-2024)

5 Market Analysis by Type
    5.1 World Human Plasma-derived Hyperimmune Product Market Size Overview by Type: 2019 VS 2023 VS 2030
    5.2 Segment Introduction by Type
        5.2.1 Hepatitis B Immunoglobulins
        5.2.2 Rabies Immunoglobulins
        5.2.3 Tetanus Immunoglobulins
        5.2.4 Rho(D) Immunoglobulins
        5.2.5 Other
    5.3 Market Segment by Type
        5.3.1 World Human Plasma-derived Hyperimmune Product Production by Type (2019-2030)
        5.3.2 World Human Plasma-derived Hyperimmune Product Production Value by Type (2019-2030)
        5.3.3 World Human Plasma-derived Hyperimmune Product Average Price by Type (2019-2030)

6 Market Analysis by Application
    6.1 World Human Plasma-derived Hyperimmune Product Market Size Overview by Application: 2019 VS 2023 VS 2030
    6.2 Segment Introduction by Application
        6.2.1 Government Institution
        6.2.2 Private Sector
        6.2.3 Others
    6.3 Market Segment by Application
        6.3.1 World Human Plasma-derived Hyperimmune Product Production by Application (2019-2030)
        6.3.2 World Human Plasma-derived Hyperimmune Product Production Value by Application (2019-2030)
        6.3.3 World Human Plasma-derived Hyperimmune Product Average Price by Application (2019-2030)

7 Company Profiles
    7.1 CSL Behring
        7.1.1 CSL Behring Details
        7.1.2 CSL Behring Major Business
        7.1.3 CSL Behring Human Plasma-derived Hyperimmune Product Product and Services
        7.1.4 CSL Behring Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.1.5 CSL Behring Recent Developments/Updates
        7.1.6 CSL Behring Competitive Strengths & Weaknesses
    7.2 Grifols
        7.2.1 Grifols Details
        7.2.2 Grifols Major Business
        7.2.3 Grifols Human Plasma-derived Hyperimmune Product Product and Services
        7.2.4 Grifols Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.2.5 Grifols Recent Developments/Updates
        7.2.6 Grifols Competitive Strengths & Weaknesses
    7.3 Biotest
        7.3.1 Biotest Details
        7.3.2 Biotest Major Business
        7.3.3 Biotest Human Plasma-derived Hyperimmune Product Product and Services
        7.3.4 Biotest Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.3.5 Biotest Recent Developments/Updates
        7.3.6 Biotest Competitive Strengths & Weaknesses
    7.4 Kedrion
        7.4.1 Kedrion Details
        7.4.2 Kedrion Major Business
        7.4.3 Kedrion Human Plasma-derived Hyperimmune Product Product and Services
        7.4.4 Kedrion Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.4.5 Kedrion Recent Developments/Updates
        7.4.6 Kedrion Competitive Strengths & Weaknesses
    7.5 CBPO
        7.5.1 CBPO Details
        7.5.2 CBPO Major Business
        7.5.3 CBPO Human Plasma-derived Hyperimmune Product Product and Services
        7.5.4 CBPO Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.5.5 CBPO Recent Developments/Updates
        7.5.6 CBPO Competitive Strengths & Weaknesses
    7.6 Emergent (Cangene)
        7.6.1 Emergent (Cangene) Details
        7.6.2 Emergent (Cangene) Major Business
        7.6.3 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Product and Services
        7.6.4 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.6.5 Emergent (Cangene) Recent Developments/Updates
        7.6.6 Emergent (Cangene) Competitive Strengths & Weaknesses
    7.7 Kamada
        7.7.1 Kamada Details
        7.7.2 Kamada Major Business
        7.7.3 Kamada Human Plasma-derived Hyperimmune Product Product and Services
        7.7.4 Kamada Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.7.5 Kamada Recent Developments/Updates
        7.7.6 Kamada Competitive Strengths & Weaknesses
    7.8 CNBG
        7.8.1 CNBG Details
        7.8.2 CNBG Major Business
        7.8.3 CNBG Human Plasma-derived Hyperimmune Product Product and Services
        7.8.4 CNBG Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.8.5 CNBG Recent Developments/Updates
        7.8.6 CNBG Competitive Strengths & Weaknesses
    7.9 Hualan Bio
        7.9.1 Hualan Bio Details
        7.9.2 Hualan Bio Major Business
        7.9.3 Hualan Bio Human Plasma-derived Hyperimmune Product Product and Services
        7.9.4 Hualan Bio Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.9.5 Hualan Bio Recent Developments/Updates
        7.9.6 Hualan Bio Competitive Strengths & Weaknesses
    7.10 Shanghai RAAS
        7.10.1 Shanghai RAAS Details
        7.10.2 Shanghai RAAS Major Business
        7.10.3 Shanghai RAAS Human Plasma-derived Hyperimmune Product Product and Services
        7.10.4 Shanghai RAAS Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.10.5 Shanghai RAAS Recent Developments/Updates
        7.10.6 Shanghai RAAS Competitive Strengths & Weaknesses
    7.11 Sichuan Yuanda Shuyang
        7.11.1 Sichuan Yuanda Shuyang Details
        7.11.2 Sichuan Yuanda Shuyang Major Business
        7.11.3 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Product and Services
        7.11.4 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.11.5 Sichuan Yuanda Shuyang Recent Developments/Updates
        7.11.6 Sichuan Yuanda Shuyang Competitive Strengths & Weaknesses
    7.12 ADMA Biologics
        7.12.1 ADMA Biologics Details
        7.12.2 ADMA Biologics Major Business
        7.12.3 ADMA Biologics Human Plasma-derived Hyperimmune Product Product and Services
        7.12.4 ADMA Biologics Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.12.5 ADMA Biologics Recent Developments/Updates
        7.12.6 ADMA Biologics Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Human Plasma-derived Hyperimmune Product Industry Chain
    8.2 Human Plasma-derived Hyperimmune Product Upstream Analysis
        8.2.1 Human Plasma-derived Hyperimmune Product Core Raw Materials
        8.2.2 Main Manufacturers of Human Plasma-derived Hyperimmune Product Core Raw Materials
    8.3 Midstream Analysis
    8.4 Downstream Analysis
    8.5 Human Plasma-derived Hyperimmune Product Production Mode
    8.6 Human Plasma-derived Hyperimmune Product Procurement Model
    8.7 Human Plasma-derived Hyperimmune Product Industry Sales Model and Sales Channels
        8.7.1 Human Plasma-derived Hyperimmune Product Sales Model
        8.7.2 Human Plasma-derived Hyperimmune Product Typical Customers

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Human Plasma-derived Hyperimmune Product Production Value by Region (2019, 2023 and 2030) & (USD Million)
    Table 2. World Human Plasma-derived Hyperimmune Product Production Value by Region (2019-2024) & (USD Million)
    Table 3. World Human Plasma-derived Hyperimmune Product Production Value by Region (2025-2030) & (USD Million)
    Table 4. World Human Plasma-derived Hyperimmune Product Production Value Market Share by Region (2019-2024)
    Table 5. World Human Plasma-derived Hyperimmune Product Production Value Market Share by Region (2025-2030)
    Table 6. World Human Plasma-derived Hyperimmune Product Production by Region (2019-2024) & (K Units)
    Table 7. World Human Plasma-derived Hyperimmune Product Production by Region (2025-2030) & (K Units)
    Table 8. World Human Plasma-derived Hyperimmune Product Production Market Share by Region (2019-2024)
    Table 9. World Human Plasma-derived Hyperimmune Product Production Market Share by Region (2025-2030)
    Table 10. World Human Plasma-derived Hyperimmune Product Average Price by Region (2019-2024) & (US$/Unit)
    Table 11. World Human Plasma-derived Hyperimmune Product Average Price by Region (2025-2030) & (US$/Unit)
    Table 12. Human Plasma-derived Hyperimmune Product Major Market Trends
    Table 13. World Human Plasma-derived Hyperimmune Product Consumption Growth Rate Forecast by Region (2019 & 2023 & 2030) & (K Units)
    Table 14. World Human Plasma-derived Hyperimmune Product Consumption by Region (2019-2024) & (K Units)
    Table 15. World Human Plasma-derived Hyperimmune Product Consumption Forecast by Region (2025-2030) & (K Units)
    Table 16. World Human Plasma-derived Hyperimmune Product Production Value by Manufacturer (2019-2024) & (USD Million)
    Table 17. Production Value Market Share of Key Human Plasma-derived Hyperimmune Product Producers in 2023
    Table 18. World Human Plasma-derived Hyperimmune Product Production by Manufacturer (2019-2024) & (K Units)
    Table 19. Production Market Share of Key Human Plasma-derived Hyperimmune Product Producers in 2023
    Table 20. World Human Plasma-derived Hyperimmune Product Average Price by Manufacturer (2019-2024) & (US$/Unit)
    Table 21. Global Human Plasma-derived Hyperimmune Product Company Evaluation Quadrant
    Table 22. World Human Plasma-derived Hyperimmune Product Industry Rank of Major Manufacturers, Based on Production Value in 2023
    Table 23. Head Office and Human Plasma-derived Hyperimmune Product Production Site of Key Manufacturer
    Table 24. Human Plasma-derived Hyperimmune Product Market: Company Product Type Footprint
    Table 25. Human Plasma-derived Hyperimmune Product Market: Company Product Application Footprint
    Table 26. Human Plasma-derived Hyperimmune Product Competitive Factors
    Table 27. Human Plasma-derived Hyperimmune Product New Entrant and Capacity Expansion Plans
    Table 28. Human Plasma-derived Hyperimmune Product Mergers & Acquisitions Activity
    Table 29. United States VS China Human Plasma-derived Hyperimmune Product Production Value Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 30. United States VS China Human Plasma-derived Hyperimmune Product Production Comparison, (2019 & 2023 & 2030) & (K Units)
    Table 31. United States VS China Human Plasma-derived Hyperimmune Product Consumption Comparison, (2019 & 2023 & 2030) & (K Units)
    Table 32. United States Based Human Plasma-derived Hyperimmune Product Manufacturers, Headquarters and Production Site (States, Country)
    Table 33. United States Based Manufacturers Human Plasma-derived Hyperimmune Product Production Value, (2019-2024) & (USD Million)
    Table 34. United States Based Manufacturers Human Plasma-derived Hyperimmune Product Production Value Market Share (2019-2024)
    Table 35. United States Based Manufacturers Human Plasma-derived Hyperimmune Product Production (2019-2024) & (K Units)
    Table 36. United States Based Manufacturers Human Plasma-derived Hyperimmune Product Production Market Share (2019-2024)
    Table 37. China Based Human Plasma-derived Hyperimmune Product Manufacturers, Headquarters and Production Site (Province, Country)
    Table 38. China Based Manufacturers Human Plasma-derived Hyperimmune Product Production Value, (2019-2024) & (USD Million)
    Table 39. China Based Manufacturers Human Plasma-derived Hyperimmune Product Production Value Market Share (2019-2024)
    Table 40. China Based Manufacturers Human Plasma-derived Hyperimmune Product Production (2019-2024) & (K Units)
    Table 41. China Based Manufacturers Human Plasma-derived Hyperimmune Product Production Market Share (2019-2024)
    Table 42. Rest of World Based Human Plasma-derived Hyperimmune Product Manufacturers, Headquarters and Production Site (States, Country)
    Table 43. Rest of World Based Manufacturers Human Plasma-derived Hyperimmune Product Production Value, (2019-2024) & (USD Million)
    Table 44. Rest of World Based Manufacturers Human Plasma-derived Hyperimmune Product Production Value Market Share (2019-2024)
    Table 45. Rest of World Based Manufacturers Human Plasma-derived Hyperimmune Product Production (2019-2024) & (K Units)
    Table 46. Rest of World Based Manufacturers Human Plasma-derived Hyperimmune Product Production Market Share (2019-2024)
    Table 47. World Human Plasma-derived Hyperimmune Product Production Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 48. World Human Plasma-derived Hyperimmune Product Production by Type (2019-2024) & (K Units)
    Table 49. World Human Plasma-derived Hyperimmune Product Production by Type (2025-2030) & (K Units)
    Table 50. World Human Plasma-derived Hyperimmune Product Production Value by Type (2019-2024) & (USD Million)
    Table 51. World Human Plasma-derived Hyperimmune Product Production Value by Type (2025-2030) & (USD Million)
    Table 52. World Human Plasma-derived Hyperimmune Product Average Price by Type (2019-2024) & (US$/Unit)
    Table 53. World Human Plasma-derived Hyperimmune Product Average Price by Type (2025-2030) & (US$/Unit)
    Table 54. World Human Plasma-derived Hyperimmune Product Production Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 55. World Human Plasma-derived Hyperimmune Product Production by Application (2019-2024) & (K Units)
    Table 56. World Human Plasma-derived Hyperimmune Product Production by Application (2025-2030) & (K Units)
    Table 57. World Human Plasma-derived Hyperimmune Product Production Value by Application (2019-2024) & (USD Million)
    Table 58. World Human Plasma-derived Hyperimmune Product Production Value by Application (2025-2030) & (USD Million)
    Table 59. World Human Plasma-derived Hyperimmune Product Average Price by Application (2019-2024) & (US$/Unit)
    Table 60. World Human Plasma-derived Hyperimmune Product Average Price by Application (2025-2030) & (US$/Unit)
    Table 61. CSL Behring Basic Information, Manufacturing Base and Competitors
    Table 62. CSL Behring Major Business
    Table 63. CSL Behring Human Plasma-derived Hyperimmune Product Product and Services
    Table 64. CSL Behring Human Plasma-derived Hyperimmune Product Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 65. CSL Behring Recent Developments/Updates
    Table 66. CSL Behring Competitive Strengths & Weaknesses
    Table 67. Grifols Basic Information, Manufacturing Base and Competitors
    Table 68. Grifols Major Business
    Table 69. Grifols Human Plasma-derived Hyperimmune Product Product and Services
    Table 70. Grifols Human Plasma-derived Hyperimmune Product Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 71. Grifols Recent Developments/Updates
    Table 72. Grifols Competitive Strengths & Weaknesses
    Table 73. Biotest Basic Information, Manufacturing Base and Competitors
    Table 74. Biotest Major Business
    Table 75. Biotest Human Plasma-derived Hyperimmune Product Product and Services
    Table 76. Biotest Human Plasma-derived Hyperimmune Product Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 77. Biotest Recent Developments/Updates
    Table 78. Biotest Competitive Strengths & Weaknesses
    Table 79. Kedrion Basic Information, Manufacturing Base and Competitors
    Table 80. Kedrion Major Business
    Table 81. Kedrion Human Plasma-derived Hyperimmune Product Product and Services
    Table 82. Kedrion Human Plasma-derived Hyperimmune Product Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 83. Kedrion Recent Developments/Updates
    Table 84. Kedrion Competitive Strengths & Weaknesses
    Table 85. CBPO Basic Information, Manufacturing Base and Competitors
    Table 86. CBPO Major Business
    Table 87. CBPO Human Plasma-derived Hyperimmune Product Product and Services
    Table 88. CBPO Human Plasma-derived Hyperimmune Product Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 89. CBPO Recent Developments/Updates
    Table 90. CBPO Competitive Strengths & Weaknesses
    Table 91. Emergent (Cangene) Basic Information, Manufacturing Base and Competitors
    Table 92. Emergent (Cangene) Major Business
    Table 93. Emergent (Cangene) Human Plasma-derived Hyperimmune Product Product and Services
    Table 94. Emergent (Cangene) Human Plasma-derived Hyperimmune Product Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 95. Emergent (Cangene) Recent Developments/Updates
    Table 96. Emergent (Cangene) Competitive Strengths & Weaknesses
    Table 97. Kamada Basic Information, Manufacturing Base and Competitors
    Table 98. Kamada Major Business
    Table 99. Kamada Human Plasma-derived Hyperimmune Product Product and Services
    Table 100. Kamada Human Plasma-derived Hyperimmune Product Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 101. Kamada Recent Developments/Updates
    Table 102. Kamada Competitive Strengths & Weaknesses
    Table 103. CNBG Basic Information, Manufacturing Base and Competitors
    Table 104. CNBG Major Business
    Table 105. CNBG Human Plasma-derived Hyperimmune Product Product and Services
    Table 106. CNBG Human Plasma-derived Hyperimmune Product Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 107. CNBG Recent Developments/Updates
    Table 108. CNBG Competitive Strengths & Weaknesses
    Table 109. Hualan Bio Basic Information, Manufacturing Base and Competitors
    Table 110. Hualan Bio Major Business
    Table 111. Hualan Bio Human Plasma-derived Hyperimmune Product Product and Services
    Table 112. Hualan Bio Human Plasma-derived Hyperimmune Product Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 113. Hualan Bio Recent Developments/Updates
    Table 114. Hualan Bio Competitive Strengths & Weaknesses
    Table 115. Shanghai RAAS Basic Information, Manufacturing Base and Competitors
    Table 116. Shanghai RAAS Major Business
    Table 117. Shanghai RAAS Human Plasma-derived Hyperimmune Product Product and Services
    Table 118. Shanghai RAAS Human Plasma-derived Hyperimmune Product Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 119. Shanghai RAAS Recent Developments/Updates
    Table 120. Shanghai RAAS Competitive Strengths & Weaknesses
    Table 121. Sichuan Yuanda Shuyang Basic Information, Manufacturing Base and Competitors
    Table 122. Sichuan Yuanda Shuyang Major Business
    Table 123. Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Product and Services
    Table 124. Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 125. Sichuan Yuanda Shuyang Recent Developments/Updates
    Table 126. ADMA Biologics Basic Information, Manufacturing Base and Competitors
    Table 127. ADMA Biologics Major Business
    Table 128. ADMA Biologics Human Plasma-derived Hyperimmune Product Product and Services
    Table 129. ADMA Biologics Human Plasma-derived Hyperimmune Product Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 130. Global Key Players of Human Plasma-derived Hyperimmune Product Upstream (Raw Materials)
    Table 131. Human Plasma-derived Hyperimmune Product Typical Customers
    Table 132. Human Plasma-derived Hyperimmune Product Typical Distributors
List of Figure
    Figure 1. Human Plasma-derived Hyperimmune Product Picture
    Figure 2. World Human Plasma-derived Hyperimmune Product Production Value: 2019 & 2023 & 2030, (USD Million)
    Figure 3. World Human Plasma-derived Hyperimmune Product Production Value and Forecast (2019-2030) & (USD Million)
    Figure 4. World Human Plasma-derived Hyperimmune Product Production (2019-2030) & (K Units)
    Figure 5. World Human Plasma-derived Hyperimmune Product Average Price (2019-2030) & (US$/Unit)
    Figure 6. World Human Plasma-derived Hyperimmune Product Production Value Market Share by Region (2019-2030)
    Figure 7. World Human Plasma-derived Hyperimmune Product Production Market Share by Region (2019-2030)
    Figure 8. North America Human Plasma-derived Hyperimmune Product Production (2019-2030) & (K Units)
    Figure 9. Europe Human Plasma-derived Hyperimmune Product Production (2019-2030) & (K Units)
    Figure 10. China Human Plasma-derived Hyperimmune Product Production (2019-2030) & (K Units)
    Figure 11. Japan Human Plasma-derived Hyperimmune Product Production (2019-2030) & (K Units)
    Figure 12. Human Plasma-derived Hyperimmune Product Market Drivers
    Figure 13. Factors Affecting Demand
    Figure 14. World Human Plasma-derived Hyperimmune Product Consumption (2019-2030) & (K Units)
    Figure 15. World Human Plasma-derived Hyperimmune Product Consumption Market Share by Region (2019-2030)
    Figure 16. United States Human Plasma-derived Hyperimmune Product Consumption (2019-2030) & (K Units)
    Figure 17. China Human Plasma-derived Hyperimmune Product Consumption (2019-2030) & (K Units)
    Figure 18. Europe Human Plasma-derived Hyperimmune Product Consumption (2019-2030) & (K Units)
    Figure 19. Japan Human Plasma-derived Hyperimmune Product Consumption (2019-2030) & (K Units)
    Figure 20. South Korea Human Plasma-derived Hyperimmune Product Consumption (2019-2030) & (K Units)
    Figure 21. ASEAN Human Plasma-derived Hyperimmune Product Consumption (2019-2030) & (K Units)
    Figure 22. India Human Plasma-derived Hyperimmune Product Consumption (2019-2030) & (K Units)
    Figure 23. Producer Shipments of Human Plasma-derived Hyperimmune Product by Manufacturer Revenue ($MM) and Market Share (%): 2023
    Figure 24. Global Four-firm Concentration Ratios (CR4) for Human Plasma-derived Hyperimmune Product Markets in 2023
    Figure 25. Global Four-firm Concentration Ratios (CR8) for Human Plasma-derived Hyperimmune Product Markets in 2023
    Figure 26. United States VS China: Human Plasma-derived Hyperimmune Product Production Value Market Share Comparison (2019 & 2023 & 2030)
    Figure 27. United States VS China: Human Plasma-derived Hyperimmune Product Production Market Share Comparison (2019 & 2023 & 2030)
    Figure 28. United States VS China: Human Plasma-derived Hyperimmune Product Consumption Market Share Comparison (2019 & 2023 & 2030)
    Figure 29. United States Based Manufacturers Human Plasma-derived Hyperimmune Product Production Market Share 2023
    Figure 30. China Based Manufacturers Human Plasma-derived Hyperimmune Product Production Market Share 2023
    Figure 31. Rest of World Based Manufacturers Human Plasma-derived Hyperimmune Product Production Market Share 2023
    Figure 32. World Human Plasma-derived Hyperimmune Product Production Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 33. World Human Plasma-derived Hyperimmune Product Production Value Market Share by Type in 2023
    Figure 34. Hepatitis B Immunoglobulins
    Figure 35. Rabies Immunoglobulins
    Figure 36. Tetanus Immunoglobulins
    Figure 37. Rho(D) Immunoglobulins
    Figure 38. Other
    Figure 39. World Human Plasma-derived Hyperimmune Product Production Market Share by Type (2019-2030)
    Figure 40. World Human Plasma-derived Hyperimmune Product Production Value Market Share by Type (2019-2030)
    Figure 41. World Human Plasma-derived Hyperimmune Product Average Price by Type (2019-2030) & (US$/Unit)
    Figure 42. World Human Plasma-derived Hyperimmune Product Production Value by Application, (USD Million), 2019 & 2023 & 2030
    Figure 43. World Human Plasma-derived Hyperimmune Product Production Value Market Share by Application in 2023
    Figure 44. Government Institution
    Figure 45. Private Sector
    Figure 46. Others
    Figure 47. World Human Plasma-derived Hyperimmune Product Production Market Share by Application (2019-2030)
    Figure 48. World Human Plasma-derived Hyperimmune Product Production Value Market Share by Application (2019-2030)
    Figure 49. World Human Plasma-derived Hyperimmune Product Average Price by Application (2019-2030) & (US$/Unit)
    Figure 50. Human Plasma-derived Hyperimmune Product Industry Chain
    Figure 51. Human Plasma-derived Hyperimmune Product Procurement Model
    Figure 52. Human Plasma-derived Hyperimmune Product Sales Model
    Figure 53. Human Plasma-derived Hyperimmune Product Sales Channels, Direct Sales, and Distribution
    Figure 54. Methodology
    Figure 55. Research Process and Data Source

Companies Mentioned

CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics